Search results
Showing 6811 to 6825 of 8314 results
Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)
This guidance has been replaced by NICE technology appraisal guidance 323.
PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)
This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
This guidance has been updated and replaced by NICE interventional procedures guidance 809.
This guidance has been updated and replaced by NICE interventional procedures guidance 809.
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)
This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.
November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.
This guidance has been updated and replaced by NICE technology appraisal guidance 1110.
This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or recently pregnant people (NG255).
This advice has been updated and replaced by NICE medical technologies guidance 42.
VitalPAC for assessing vital signs of patients in hospital (MIB79)
This advice has been updated and replaced by NICE medtech innovation briefing 205.
This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.
Lutonix drug-coated balloon for peripheral arterial disease (MIB72)
NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.